Cell-based delivery systems: Development of encapsulated cell technology for ophthalmic applications

Weng Tao, Rong Wen, Alan Laties, Gustavo D. Aguirre

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Scopus citations

Abstract

Encapsulated cell technology (ECT) was developed to treat diseases of the central nervous system (CNS) (1–10) and the eye (11). ECT implants consist of living cells encapsulated within a semipermeable polymer membrane and supportive matrices. The encapsulated cells are genetically engineered to produce a specific therapeutic substance to target a specific disease or condition. Once surgically implanted into the CNS or eye, the semipermeable polymer membrane has two main functions: it allows the outward passage of the therapeutic product while protecting the encapsulated cells from rejection by the patient’s immune system. It also permits ready access to oxygen and nutrients (Fig. 1).

Original languageEnglish (US)
Title of host publicationIntraocular Drug Delivery
PublisherCRC Press
Pages111-128
Number of pages18
ISBN (Electronic)9781420016505
ISBN (Print)9780824728601
StatePublished - Jan 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Cell-based delivery systems: Development of encapsulated cell technology for ophthalmic applications'. Together they form a unique fingerprint.

  • Cite this

    Tao, W., Wen, R., Laties, A., & Aguirre, G. D. (2006). Cell-based delivery systems: Development of encapsulated cell technology for ophthalmic applications. In Intraocular Drug Delivery (pp. 111-128). CRC Press.